Brent Warner
2022
In 2022, Brent Warner earned a total compensation of $2.9M as President, Gene Therapy at Poseida Therapeutics.
Compensation breakdown
| Non-Equity Incentive Plan | $162,920 |
|---|---|
| Option Awards | $1,051,982 |
| Salary | $370,278 |
| Stock Awards | $1,052,953 |
| Other | $240,895 |
| Total | $2,879,028 |
Warner received $1.1M in stock awards, accounting for 37% of the total pay in 2022.
Warner also received $162.9K in non-equity incentive plan, $1.1M in option awards, $370.3K in salary and $240.9K in other compensation.
Rankings
In 2022, Brent Warner's compensation ranked 1,262nd out of 5,760 executives tracked by ExecPay. In other words, Warner earned more than 78.1% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 1,262 out of 5,760 | 78th |
Division Manufacturing | 617 out of 3,136 | 80th |
Major group Chemicals And Allied Products | 228 out of 1,422 | 84th |
Industry group Drugs | 207 out of 1,323 | 84th |
Industry Biological Products, Except Diagnostic Substances | 49 out of 291 | 83rd |
Source: SEC filing on April 26, 2023.
Warner's colleagues
We found three more compensation records of executives who worked with Brent Warner at Poseida Therapeutics in 2022.